High levels of soluble programmed death-1 are associated with virological response in chronic hepatitis B patients after antiviral treatment

Tan, Ning; Luo, Hao; Kang, Qian; Pan, Jiali; Cheng, Ran; Xi, Hongli; Chen, Hongyu; Han, Yanxi; Yang, Yuqing; Xu, Xiaoyuan

doi:10.1016/j.virusres.2021.198660

Cited by 5 publications

(4 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Besides, high sPD-1 levels were demonstrated to associated with a high risk of developing HCC. [20][21][22] Those results suggest that sPD-1 may be associated with disease activity and involved in disease progression in chronic HBV infection. However, there are few relevant studies, and the ability of serum sPD-1 to predict liver in ammation in CHB patients is still unclear.…”

Section: Introductionmentioning

confidence: 73%

Soluble Programmed Cell Death 1 Protein is a Promising Biomarker to Predict Severe Liver Inflammation in Chronic Hepatitis B Patients

Ou,

Zhang,

Pan

et al. 2023

Preprint

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 73%

Soluble Programmed Cell Death 1 Protein is a Promising Biomarker to Predict Severe Liver Inflammation in Chronic Hepatitis B Patients

Ou,

Zhang,

Pan

et al. 2023

Preprint

View full text Add to dashboard Cite

“…Besides, high sPD-1 levels were demonstrated to be associated with a high risk of developing HCC. 20 − 22 These results suggest that sPD-1 may be associated with disease activity and is involved in disease progression in chronic HBV infections. However, there are few relevant studies, and the ability of serum sPD-1 to predict liver inflammation in CHB patients is still unclear.…”

Section: Introductionmentioning

confidence: 82%

“…Recent studies have shown that sPD-1 is elevated in infectious, inflammatory, and autoimmune diseases and associated with the disease activity. − In chronic HBV infection, sPD-1 is also elevated and correlates with the levels of liver enzymes and the virological response. Besides, high sPD-1 levels were demonstrated to be associated with a high risk of developing HCC. − These results suggest that sPD-1 may be associated with disease activity and is involved in disease progression in chronic HBV infections. However, there are few relevant studies, and the ability of serum sPD-1 to predict liver inflammation in CHB patients is still unclear.…”

Section: Introductionmentioning

confidence: 99%

Soluble Programmed Cell Death 1 Protein Is a Promising Biomarker to Predict Severe Liver Inflammation in Chronic Hepatitis B Patients

Ou,

Zhang,

Zhang

et al. 2024

ACS Omega

View full text Add to dashboard Cite

Background and Aims: Liver inflammation is important in guiding the initiation of antiviral treatment and affects the progression of chronic hepatitis B(CHB). The soluble programmed cell death 1 protein (sPD-1) was upregulated in inflammatory and infectious diseases and correlated with disease severity. We aimed to investigate the correlation between serum sPD-1 levels and liver inflammation in CHB patients and their role in indicating liver inflammation. Methods: 241 CHB patients who underwent liver biopsy were enrolled. The correlation between sPD-1 levels and the degree of liver inflammation was analyzed. Univariate and multivariate logistic regression analyses were performed to analyze independent variables of severe liver inflammation. Binary logistic regression analysis was conducted to construct a predictive model for severe liver inflammation, and the receiver operating characteristic curve (ROC) was used to evaluate the diagnostic accuracy of the predictive model. Results: sPD-1 was highest in CHB patients with severe liver inflammation, which was higher than that in CHB patients with mild or moderate liver inflammation (P < 0.001). Besides, sPD-1 was weakly correlated with AST (r = 0.278, P < 0.001). Multivariable analysis showed that sPD-1 was an independent predictor of severe liver inflammation. The predictive model containing sPD-1 had areas under the ROC (AUROCs) of 0.917 and 0.921 in predicting severe liver inflammation in CHB patients and CHB patients with ALT ≤ 1× upper limit of normal (ULN), respectively. Conclusions: Serum sPD-1 level is associated with liver inflammation in CHB patients, and high levels of sPD-1 reflect severe liver inflammation. Serum sPD-1 is an independent predictor of severe liver inflammation and shows improved diagnostic accuracy when combined with other clinical indicators.

show abstract

“…Zhou L et al 19 reported that sPD-1 positively correlated with HBsAg levels during antiviral treatment in CHB patients with treatment naive. However, Tian N et al 35 recently showed that sPD-1 levels negatively correlated with HBsAg levels in CHB patients with antiviral treatment. Our study showed that sPD-1 levels were negatively correlated with HBsAg level, but weakly or not statistically significant.…”

Section: Discussionmentioning

confidence: 98%

Soluble Programmed Cell Death-1 is a Novel Predictor of HBsAg Loss in Chronic Hepatitis B Patients When Long-Term Nucleos(t)ide Analog Treatment is Discontinued

Liao¹,

Liu²,

Xia³

et al. 2022

IDR

View full text Add to dashboard Cite

Purpose The immunoinhibitory receptor, programmed death 1 (PD-1), plays a critical role in immune suppression during chronic viral infection. The significance of circulating soluble PD-1 (sPD-1) in patients with chronic hepatitis B who have discontinued long-term nucleos(t)ide analog (NA) treatment remains unknown. Patients and Methods A prospective cohort study was conducted using serial blood samples from chronic hepatitis B patients who discontinued long-term NA treatment. The current analysis included 115 non-cirrhotic patients with HBV DNA negative and HBsAg positive at the moment of NA discontinuation. Levels of sPD-1 were measured in all available samples using sandwich enzyme-linked immunoassay. Results Sixty-two patients experienced a clinical relapse and 14 occurred HBsAg loss, with 8-year cumulative rates of 56.6% and 23.4%, respectively. Time-dependent receiver operating characteristic curve analysis for sPD-1 derived 156 pg/mL, which is equivalent to the detectable threshold, as an optimal cut-off value for predicting 8-year clinical relapse. Patients with detectable sPD-1 at end of treatment (EOT) had a significant lower incidence of clinical relapse (48% vs 67%, hazard ratio [HR] 0.454, p = 0.006), but a remarkable higher probability of HBsAg loss (33.7% vs 2.4%, HR 9.17, p = 0.038), compared to those who with undetectable sPD-1, respectively. Conclusion EOT sPD-1 levels predicted clinical relapse and HBsAg loss after treatment discontinuation and may help to guide a finite NA treatment plan for patients with chronic hepatitis B virus infection.

show abstract

High levels of soluble programmed death-1 are associated with virological response in chronic hepatitis B patients after antiviral treatment

Cited by 5 publications

References 21 publications

Soluble Programmed Cell Death 1 Protein is a Promising Biomarker to Predict Severe Liver Inflammation in Chronic Hepatitis B Patients

Soluble Programmed Cell Death 1 Protein is a Promising Biomarker to Predict Severe Liver Inflammation in Chronic Hepatitis B Patients

Soluble Programmed Cell Death 1 Protein Is a Promising Biomarker to Predict Severe Liver Inflammation in Chronic Hepatitis B Patients

Soluble Programmed Cell Death-1 is a Novel Predictor of HBsAg Loss in Chronic Hepatitis B Patients When Long-Term Nucleos(t)ide Analog Treatment is Discontinued

Contact Info

Product

Resources

About